The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patients
European Journal of Cancer, ISSN: 0959-8049, Vol: 29, Issue: SUPPL. 1, Page: S2-S6
1993
- 16Citations
- 14Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations16
- Citation Indexes15
- 15
- CrossRef11
- Policy Citations1
- 1
- Captures14
- Readers14
Article Description
Fluoroquinolones are the most attractive agents for prophylactic use in neutropenic cancer patients, due to their broad antimicrobial spectrum, high concentration in the faeces, systemic bactericidal activity, uncommon emergence of resistant strains and good tolerability. They have proved to be more effective than placebo, oral non-absorbable antibiotics or cotrimoxazole in the prevention of Gram-negative infections. In a prospective, randomised multicentre study performed by the GIMEMA infection program, ciprofloxacin was demonstrated to be more effective than norfloxacin for the reduction of febrile episodes, use of systemic antibiotics, and Gram-negative infections in neutropenic patients with haematological malignancies. The greater efficacy may be related to its better systemic or greater antibacterial activity. The potential problems related to the prophylactic use of fluoroquinolones are the increasing prevalence of Gram-positive infections caused by streptococci and coagulase-negative staphylococci; the reported emergence and nosocomial spread of resistant strains, especially among coagulase-negative staphylococci; the lack of their usefulness as empirical therapy in febrile neutropenic patients. Fluoroquinolones are today the better choice for preventing Gram-negative infections in neutropenic patients and ciprofloxacin should probably be preferred. More information on their efficacy and their relationship to the overall susceptibility of micro-organisms in patients with cancer would be valuable, and careful monitoring of patients treated with these drugs is therefore warranted.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0959804905802527; http://dx.doi.org/10.1016/s0959-8049(05)80252-7; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0342609017&origin=inward; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0027082458&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/8427721; https://linkinghub.elsevier.com/retrieve/pii/S0959804905802527; http://linkinghub.elsevier.com/retrieve/pii/S0959804905802527; http://api.elsevier.com/content/article/PII:S0959804905802527?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S0959804905802527?httpAccept=text/plain; http://dx.doi.org/10.1016/s0959-8049%2805%2980252-7; https://dx.doi.org/10.1016/s0959-8049%2805%2980252-7
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know